Compare Marvell Technology Inc (MRVL) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs Philip Morris International Inc. — how do they compare? Marvell Technology Inc trades at $280.51 (market cap $246.84B), while Philip Morris International Inc. trades at $199.94 (market cap $312.50B). The key difference: Philip Morris International Inc. is the larger of the two by market cap, and Philip Morris International Inc. pays the higher dividend (3.19%). Which is the better fit depends on your goals — on Pluang, investors hold Marvell Technology Inc for 42 Days and Philip Morris International Inc. for 85 Days on average.
| MRVL | PM | |
|---|---|---|
Market Cap | $246.84B | $312.50B |
Volume | 29,003,830 | 5,517,172 |
Sector | Technology | Consumer Staples |
52-Week High | $316.43 | $200.50 |
52-Week Low | $73.73 | $144.33 |
Typical Hold Time | 42 Days | 85 Days |
Enterprise Value | $248.19B | $355.62B |
Dividend Yield | 0.09% | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $284.68, down 0.81% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 expected at $1.1. Revenue growth is accelerating, driven by data center and custom AI chip demand, though current valuations are elevated with a P/E of 90.95. Recent news highlights a major Google deal and raised fiscal 2028 revenue guidance to $18 billion.
The outlook remains positive given robust AI infrastructure spending and management's optimistic forecasts. Key risks include high valuation multiples, competitive pressures, and execution challenges in scaling custom chip production. Analyst consensus is strongly bullish with a $327.86 price target, suggesting significant upside potential if growth targets are met.
Philip Morris International (PM) trades at $192.69, up 1.2% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 EPS beat expectations at $2.20 vs. $2.05, and revenue growth accelerated to $40.65B in 2025. The company's smoke-free products now drive 42% of revenue, with ZYN and IQOS expansions fueling optimism. Cash flow remains robust, with 2026 operating cash flow projected at $14.3B, supporting dividend growth.
Outlook is positive given earnings momentum and smoke-free transition, but high debt ($42.17B long-term) and regulatory risks persist. The consensus price target of $212.17 implies ~10% upside, though valuation multiples are elevated versus peers. Key risks include FX volatility and slower adoption of next-gen products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
